Alembic Pharmaceuticals has published its audited consolidated financial results for the quarter and financial year ended 31st March, 2026, filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in Economic Times, Indian Express (English Edition), and Financial Express (Gujarati Edition) on 16th May, 2026. The company reported year-on-year growth in consolidated net profit and revenue for Q4 FY26, alongside a strong full-year performance. Following the results, management shared forward-looking guidance across key business segments during a concall update.

Q4 FY26 Consolidated Financial Performance

For the quarter ended 31st March, 2026, Alembic Pharmaceuticals reported consolidated total income from operations of ₹1,847.72 crores, compared to ₹1,769.64 crores in the corresponding quarter of the previous year. Consolidated net profit after tax attributable to shareholders stood at ₹202.70 crores, up from ₹156.89 crores in the year-ago quarter, reflecting a meaningful improvement in bottom-line performance. Total comprehensive income for the quarter came in at ₹213.07 crores, against ₹162.17 crores in the prior-year period. Basic and diluted earnings per share (face value ₹2/- each) for the quarter rose to ₹10.31 from ₹7.98 year-on-year.

The table below summarises the key consolidated financial metrics for Q4 FY26:

Full-Year FY26 Consolidated Results

For the full financial year ended 31st March, 2026, Alembic Pharmaceuticals reported consolidated total income from operations of ₹7,344.90 crores. Net profit before tax and exceptional items stood at ₹760.94 crores, while net profit before tax after exceptional items was ₹693.95 crores. Net profit after tax attributable to shareholders for FY26 came in at ₹674.77 crores, with total comprehensive income at ₹695.69 crores. Reserves (excluding revaluation reserve) as shown in the audited balance sheet stood at ₹5,635.50 crores, and full-year basic and diluted EPS was ₹34.33.

Standalone Financial Highlights

On a standalone basis, Alembic Pharmaceuticals reported total income from operations of ₹1,718.74 crores for Q4 FY26, compared to ₹1,570.64 crores in Q4 FY25. Profit before exceptional item and tax for the quarter stood at ₹198.21 crores, significantly higher than ₹91.56 crores in the year-ago period. Standalone profit after tax for Q4 FY26 came in at ₹243.07 crores, compared to ₹75.34 crores in the corresponding prior-year quarter. For the full year FY26, standalone total income from operations was ₹6,651.38 crores, with profit before exceptional item and tax at ₹721.10 crores and profit after tax at ₹640.42 crores.

FY27 Business Outlook and Segment Guidance

During the concall update, Alembic Pharmaceuticals' management outlined its growth targets for FY27 across key business segments. The company targets low double-digit revenue growth overall for FY27. The international generics business is expected to grow in the low to mid-teen range, while the API business is anticipated to grow in the high single or low double-digit range. The India business is aiming for growth aligned with market trends. The international business also plans several key product launches spread throughout the year, including major launches in early quarters.

The company also expects significant revenue growth from its US-branded business in coming quarters, with margin improvements anticipated to counter launch-based impacts. The table below summarises the FY27 segment-wise growth guidance:

R&D and Capital Expenditure Plans

For FY27, Alembic Pharmaceuticals projects R&D spending in the range of ₹750 crores to ₹800 crores, aiming for a revenue return of approximately 9%. Capital expenditure for FY27 is estimated at ₹300 crores to ₹350 crores, focused on capacity improvements and replacement.

The detailed financial results are available on the stock exchanges' websites and on the company's website at alembicpharmaceuticals.com/quarterly-results. The results were signed by Chairman Chirayu Amin from Vadodara, dated 15th May, 2026.

Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practice (GMP) inspection conducted by Brazil's National Health Surveillance Agency, Anvisa, at its Karakhadi API-III facility. The inspection encompassed multiple active pharmaceutical ingredients (APIs), all of which were completed without any observations or issues.

Regulatory Milestone at Karakhadi API-III

The successful passage of the Anvisa GMP inspection at the Karakhadi API-III facility underscores the company's adherence to international manufacturing and quality standards. Anvisa, as Brazil's primary health regulatory authority, conducts rigorous GMP inspections to ensure that pharmaceutical manufacturing sites comply with global quality benchmarks before their products can be approved for the Brazilian market.

The following key details summarize the inspection outcome:

Significance of the Anvisa Clearance

Passing an Anvisa GMP inspection is a critical step for pharmaceutical manufacturers seeking to supply active pharmaceutical ingredients to the Brazilian market, one of the largest pharmaceutical markets in Latin America. A clean inspection outcome — with no observations or deficiencies noted — reflects positively on the quality systems and manufacturing practices maintained at the Karakhadi API-III site.

Alembic Pharmaceuticals' ability to clear this inspection for multiple APIs simultaneously further highlights the operational readiness and compliance posture of the facility. This clearance is expected to support the company's regulatory standing with Anvisa and its broader presence in regulated international markets.